The Enforcement Pipeline Nobody Shows You
We audit banned peptide ad accounts every week. We see the same patterns over and over, and once you understand the enforcement pipeline, the bans stop being mysterious. They become predictable.
Most advertisers treat a ban as a random event. It is not. Meta and Google both run automated enforcement systems that scan every peptide ad for a specific set of triggers. When you trip one of those triggers, the ban is algorithmic, not editorial. Understanding which triggers are wired to which enforcement actions is the difference between campaigns that last six months and campaigns that last six hours.
How the Automated Enforcement Systems Actually Work
Meta's system operates in three layers. The first is a keyword scanner that checks ad copy against a restricted substance list. Peptides like BPC-157, semaglutide, and tirzepatide are all on that list. The second layer is a classification model that assigns a risk score based on how closely your ad resembles previously banned ads in the same category. The third layer is the landing page scanner, which crawls every URL your ad links to and applies the same classification model to the page content.
Google's system works differently. It uses the healthcare and medicines certification as a gate. If you have not completed certification, no ad runs. If you have completed it, the system still scans for prescription drug content, unsubstantiated claims, and prohibited business practices. Google's review pipeline is slower than Meta's but less likely to produce false positives if your certification and landing page are both clean.
On both platforms, the automated system makes the initial decision. Human reviewers only get involved when you appeal. This means your first submission has to pass the bots before a person ever sees it.
The Five Triggers That Cause Most Bans
Trigger one: Drug name mentions. Using Ozempic, Wegovy, Mounjaro, BPC-157, or any specific peptide name in ad copy triggers immediate automated rejection on both Meta and Google. The bots do not parse intent. They see the name and flag the ad.
Trigger two: Health outcome claims. Any language suggesting weight loss, muscle growth, anti-aging, or treatment of a condition gets flagged. This includes implied claims like 'support your metabolic health' when paired with a product image.
Trigger three: Landing page mismatches. Your ad can be perfectly compliant, but if the landing page makes claims the ad does not, both platforms will reject the ad. Meta and Google both crawl landing pages as part of ad review.
Trigger four: Unverified business documentation. If your pharmacy license, business registration, or domain ownership records are not on file through BAV or equivalent verification, your account operates at heightened scrutiny. Every ad gets a default risk bump before review even starts.
Trigger five: Account history. Previous bans on your ad account or Business Manager create a history score. Accounts with prior enforcement actions face faster automated rejections on new ads. This is the hardest trigger to neutralize because it is a cumulative score, not a binary flag.
What the Regulations Actually Require
FDA 503A governs compounding pharmacies preparing medications for individual patients. Under 503A, you cannot advertise compounded drugs as FDA-approved. You can advertise the availability of compounding services and mention that medications are prepared under FDA-regulated conditions. The distinction between 'FDA-approved' and 'FDA-regulated' is the single most important regulatory concept in peptide advertising.
FDA 503B covers outsourcing facilities that compound at scale. The advertising restrictions are essentially the same as 503A, but 503B facilities face additional requirements around sterility documentation and batch records. If your ad mentions sterile compounding or batch production, you need to ensure your quality documentation is current before running ads.
DSHEA 1994 applies if your peptides are marketed as dietary supplements. Under Section 3, you cannot claim a supplement treats, cures, or prevents any disease. Structure-function claims are allowed but require the FDA disclaimer: 'This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.'
The BAV appeal pathway is your primary tool for challenging automated bans. Verified businesses get access to a higher review tier and face fewer automated rejections. We complete BAV verification for every client before running a single ad.
How We Fixed a Client Who Was Banned Five Times in Three Months
A compounding pharmacy client came to us with five banned ad accounts across two Business Managers. Every time they launched a new campaign featuring tirzepatide and semaglutide, the ads would run for 48 hours and then get rejected for 'circumventing systems.' The client had rebuilt their ad accounts from scratch each time, never addressing the underlying triggers.
We traced the problem to three specific issues. First, their landing page included dosing guidance and weight loss outcome language buried in a PDF download. Meta's crawler found the PDF and flagged the entire domain. Second, their Business Manager had accumulated enough enforcement actions that every new ad account inherited a risk score near the top of the automated rejection threshold. Third, they had never completed BAV verification.
We built a new landing page stripped of all dosing and outcome language. We completed BAV verification with their pharmacy license and state registration. We created a new Business Manager with a clean history and launched educational ads focused on compounding service availability, not the compounds themselves. The ads ran continuously for seven months without a single ban.
More reading
Peptide Advertising Regulations
Peptide Facebook Ads Disapproved
Ready to run these ads? Book a call → calendly.com/custodio-2/30min